Two New HIV Studies Give Access to Research Medications to People with Multi-Drug Resistance
By Nelson Vergel. SalvageTherapies.org
No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiou sly wait for access to lifesaving ARVs that would finally control their viral (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - September 10, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Webcast : Beyond the Berlin Patient- How Researchers Are Now Trying to Cure More HIV+ People
Webcast : Beyond the Berlin Patient- How Researchers Are
Now Trying to Cure More HIV+ People
By Nelson Vergel
We all read
headlines almost weekly about the latest HIV cure. After years of being exposed to these
inflamed news reports, we may get desensitized to the fact that there is
actually progress being made in that field.
Ever since Timothy Brown was proven to be cured, the (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - September 9, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Two New HIV Studies Give Access to Research Medications to People with Multi-Drug Resistance
By Nelson Vergel. SalvageTherapies.org
No one can deny that many patients can now suppress their HIV with effective antiretrovirals (ARVs) that cause fewer side effects. However, a vulnerable and often forgotten minority of people are still struggling with multi-drug resistant HIV (MDR-HIV) while they anxiously wait for access to lifesaving ARVs that would finally control their viral (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - September 9, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Webcast Transcript: All You Need to Know About the Use of Truvada to Prevent HIV Infection (Pre-Exposure Prophylaxis- PrEP)
TRANSCRIPT FROM GOOGLE HANGOUT ON HIV PRE-EXPOSURE PROPHYLAXIS
(PrEP) WITH DAMON JACOBS AND NELSON VERGEL
Scott: Hello everybody. Scott Sillary here with Viral Marketing. I'm here
with Nelson Vergel and Damon Jacobs. Welcome to the Power Hangout. It's going
to be fan tastic. Nelson, tell us a little bit about what we're going to be
going through today.
Nelson: (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 28, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Webcast Transcript: All You Need to Know About the Use of Truvada to Prevent HIV Infection (Pre-Exposure Prophylaxis- PrEP)
TRANSCRIPT FROM GOOGLE HANGOUT ON HIV PRE-EXPOSURE PROPHYLAXIS
(PrEP) WITH DAMON JACOBS AND NELSON VERGEL
Scott: Hello everybody. Scott Sillary here with Viral Marketing. I'm here
with Nelson Vergel and Damon Jacobs. Welcome to the Power Hangout. It's going
to be fantastic. Nelson, tell us a little bit about what we're going to be
going through today.
Nelson: (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - August 27, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT)
Activists and educators Damon Jacobs and Nelson Vergel will answer questions about the use of Truvada for HIV Pre-Exposure Prophylaxis (PrEP) covering research facts, misconceptions and access of this highly effective prevention tool. This webcast is of interest to the lay person and clinicians. P lease RSVP by clicking "Yes" (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 23, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
The HIV Prevention Pill: A Free Webcast on July 29, 6:30 PM (EDT)
Activists and educators Damon Jacobs and Nelson Vergel will answer questions about the use of Truvada for HIV Pre-Exposure Prophylaxis (PrEP) covering research facts, misconceptions and access of this highly effective prevention tool. This webcast is of interest to the lay person and clinicians. Please RSVP by clicking "Yes" (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - July 22, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
Frapsauce C, et al. Hum Reprod. 2015.
Authors
Frapsauce C1, Grabar S2, Leruez-Ville M3, Launay O4, Sogni P5, Gayet V6, Viard JP7, De Almeida M8, Jouannet P8, Dulioust E1.Author information
1Laboratoire de Biologie de la Reproduction, Hôpital Broca-Cochin-Hôtel Dieu, Assistance Publique-H ôpitaux de (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 24, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
Frapsauce C, et al. Hum Reprod. 2015.
Authors
Frapsauce C1, Grabar S2, Leruez-Ville M3, Launay O4, Sogni P5, Gayet V6, Viard JP7, De Almeida M8, Jouannet P8, Dulioust E1.Author information
1Laboratoire de Biologie de la Reproduction, Hôpital Broca-Cochin-Hôtel Dieu, Assistance Publique-Hôpitaux de (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - June 23, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BM S-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed's (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 16, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.
Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed's (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 15, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Starting HIV Medications Within First Weeks of Infection Decreases Hidden Virus
Clin Infect Dis. (2015) doi: 10.1093/cid/civ171First published online: March 3, 2015
Impact of the Earliness of Antiretroviral Therapy Initiation During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA
Moussa Laanani1,2,
1Inserm, CESP Centre for Research i n Epidemiology and Population Health, U1018, Paris-Sud University, Le Kremlin-Bicêtre, France
2APHP, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 4, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Starting HIV Medications Within First Weeks of Infection Decreases Hidden Virus
Clin Infect Dis. (2015) doi: 10.1093/cid/civ171First published online: March 3, 2015
Impact of the Earliness of Antiretroviral Therapy Initiation During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA
Moussa Laanani1,2,
1Inserm, CESP Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University, Le Kremlin-Bicêtre, France
2APHP, (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 3, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Most Important HIV Research Reports from CROI 2015
From Jules Levin: perhaps the biggest stories out of CROI from my perspective are the development of 2 new HIV therapies - the new attachment inhibitor& the new maturation inhibitors, as well as the safety& efficacy of TAF, and an important message out of CROI is that TAF can also be used in HCV coinfected patients as a replacement for TDF in their ART regimen which will likely (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 3, 2015 Category: Infectious Diseases Authors: Anonymous Source Type: blogs
Most Important HIV Research Reports from CROI 2015
From Jules Levin: perhaps the biggest stories out of CROI from my perspective are the development of 2 new HIV therapies - the new attachment inhibitor & the new maturation inhibitors, as well as the safety & efficacy of TAF, and an important message out of CROI is that TAF can also be used in HCV coinfected patients as a replacement for TDF in their ART regimen which will likely (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - March 2, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
